Prothena (PRTA) to Release Earnings on Thursday

Prothena (NASDAQ:PRTA) will post its quarterly earnings results after the market closes on Thursday, August 8th. Analysts expect Prothena to post earnings of ($1.01) per share for the quarter.

Prothena (NASDAQ:PRTA) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.13). The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $3.75 million. Prothena had a negative return on equity of 30.48% and a negative net margin of 193.17%. During the same quarter in the previous year, the company posted ($0.89) earnings per share. On average, analysts expect Prothena to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Prothena Stock Up 4.1 %

PRTA stock traded up $0.81 during trading on Tuesday, hitting $20.59. The company had a trading volume of 137,471 shares, compared to its average volume of 639,781. The firm has a 50-day moving average price of $21.60 and a 200-day moving average price of $24.05. Prothena has a 12 month low of $18.69 and a 12 month high of $63.64. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -6.09 and a beta of 0.21.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Royal Bank of Canada restated a “sector perform” rating and set a $28.00 target price on shares of Prothena in a research report on Wednesday, June 26th. HC Wainwright cut their price objective on shares of Prothena from $90.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. JMP Securities cut their target price on Prothena from $85.00 to $83.00 and set a “market outperform” rating on the stock in a research note on Thursday, May 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Prothena in a research report on Wednesday, April 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Prothena currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.00.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.